Eli Lilly (LLY)
1,225.73
+42.57 (3.60%)
NYSE· Last Trade: Aug 18th, 9:35 PM EDT
Detailed Quote
| Previous Close | 1,183.16 |
|---|---|
| Open | 1,200.00 |
| Bid | 1,223.75 |
| Ask | 1,226.00 |
| Day's Range | 1,194.01 - 1,228.47 |
| 52 Week Range | 685.15 - 1,249.45 |
| Volume | 2,509,057 |
| Market Cap | 1.17T |
| PE Ratio (TTM) | 53.41 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.56%) |
| 1 Month Average Volume | 2,618,565 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiri...
Via StockStory · August 18, 2026
PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.
Via The Motley Fool · August 18, 2026
Issued on behalf of Conexeu Sciences Inc.
By Equity Insider · Via GlobeNewswire · August 18, 2026
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
Via The Motley Fool · August 18, 2026
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.
Via The Motley Fool · August 18, 2026
Outpatient physical therapy operators regularly strengthen their executive leadership to support long-term operational scaling and strategic financial mana
Via Talk Markets · August 18, 2026
Investors can reap big rewards over the long term by betting on growth in their younger years.
Via The Motley Fool · August 18, 2026
August 17, 2026 — VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention as its 3D human tissue models, artificial intelligence and New Approach Methodologies (NAMs) target one of pharmaceutical development’s biggest challenges: identifying drug toxicity before costly clinical trials.
Via AB Newswire · August 17, 2026
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
Via Benzinga · August 17, 2026
The S&P 500 returned 9.5% annually over the past two decades. Wall Street expects much bigger gains in the next year.
Via The Motley Fool · August 17, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via StockStory · August 17, 2026
They are fairly risky, but their potential upside is massive.
Via The Motley Fool · August 16, 2026
The company's peers in the pharmaceutical industry should be worried.
Via The Motley Fool · August 15, 2026
They are way more than just GLP-1 stocks.
Via The Motley Fool · August 14, 2026
The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker.
Via The Motley Fool · August 14, 2026
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
Via The Motley Fool · August 14, 2026
New product launches drove 5% revenue growth and margin expansion.
Via The Motley Fool · August 13, 2026
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.
Via The Motley Fool · August 13, 2026
Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.
Via The Motley Fool · August 13, 2026
The stock continues to look unstoppable.
Via The Motley Fool · August 13, 2026
It's yet another setback for the drugmaker.
Via The Motley Fool · August 13, 2026
FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.
Via The Motley Fool · August 13, 2026
Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.
Via The Motley Fool · August 12, 2026
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
Via The Motley Fool · August 12, 2026
It has proven to be a market-beater in more years than not.
Via The Motley Fool · August 12, 2026